USPs that matters:

$kyrocking Ca$hcows

AI triggered Signals

ETF InfoDataHub

Visit our new ATH Index-Gate

White Label as a Service

IPO InfoDataHub

Short Selling Radar

Turnkey solutions: ayondo Franchise

& more ...

Tipp: Hedge Fund Activity Tracker ("HFAT")

Newswire
Directors Dealings
DD i/o
Short Selling Radar
HFAT
WWR
FTT
NewAD
Ratings
Vola-Statistics

Tools

Tools/Apps
Lab

Education
Webinars
Mentoring

Press

FAQ

What's New

EN
DE

Company
- About Us
- Vision/Mission
- IR
- Press
- Career
- Specials
Portfolio
Product
- CFD/FX
- Indices
- Currencies
- Commodities
- Metals
- Stocks & ETFs
- Crypto
- ETP/ETI
- Financial Innovations
Platforms
Institutional/B2B

Login Register

Home
Terminal
UroGen Pharma Ltd.

UroGen Pharma Ltd.

WHO'M

ai

Digital Profiler. Simply click the AI button

CUSIP

001140714

SEDOL

BF2HFS6

CIK

0001668243

www.urogen.com

LEI:

FIGI: BBG00GFCC613

URGN

UroGen Pharma Ltd.

GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology

AI

PROFILER

BASIC = Free ADVANCED = User Account BUSINESS = Subscription PRIME = Subscription

ENTERPRISE = upon request

AI

PROFILER

BASIC

ADVANCED

BUSINESS

PRIME

AI Insights

UroGen Pharma

Click to initiate

ENTERPRISE

NAME

UroGen Pharma Ltd.

ISIN

IL0011407140

TICKER

URGN

MIC

XNAS

REUTERS

URGN.OQ

BLOOMBERG

URGN US

BUILD THEMEFOLIO SHARE IDEAS DISCUSS

LEVERAGE INVEST

Financial Intelligence

360°^iHub Crowd^iFeed ATH Tracker Index Tracker ETF TF Spicy² X-Billboard

X-OVR
FACTSHEET
PEERGROUP
X-News Explorer
L/S SHORT
STUDY
ROOTS
IT’s ME

FOR INVESTORS

FOR TRADERS

Securities Trading Warrants

Directors Dealings

X-Billboard

EQS Newswire

Globe Newswire

PR Newswire

BusinessWire

ACCESS Newswire

ActuNews

Newsfile

EDGAR

The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.

Mon, 10.03.2025 UroGen Pharma

IL0011407140

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided an overview of recent developments. “2024 was a pivotal year for UroGen with...

Read More

UroGen Pharma

Technical Analysis Termsheet Terminal

Permalink

Fri, 07.03.2025 UroGen Pharma

IL0011407140

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 7 new employees in connection with their employment with UroGen. These new team members will support the ongoi...

Read More

UroGen Pharma

Technical Analysis Termsheet Terminal

Permalink

Thu, 27.02.2025 UroGen Pharma

IL0011407140

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2024 financial results on Monday, March 10, 2025, prior to the open of the stock market. The announcement will be followe...

Read More

UroGen Pharma

Technical Analysis Termsheet Terminal

Permalink

Mon, 24.02.2025 UroGen Pharma

IL0011407140

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference to take place on March 3-5, 2025. TD Cowen 45th Annual Health Care Confer...

Read More

UroGen Pharma

Technical Analysis Termsheet Terminal

Permalink

Thu, 20.02.2025 UroGen Pharma

IL0011407140

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced expansion of its oncology pipeline portfolio through the acquisition of assets relating to a next-generation oncolytic virus ICVB-1042 from IconOVir Bio, Inc. (IconOVir)....

Read More

UroGen Pharma

Technical Analysis Termsheet Terminal

Permalink

Fri, 14.02.2025 UroGen Pharma

IL0011407140

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from the subgroup analyses of the pivotal ENVISION study evaluating the impact of tumor burden and focality on the response to UGN-102, an investigational drug in...

Read More

UroGen Pharma

Technical Analysis Termsheet Terminal

Permalink

Wed, 12.02.2025 UroGen Pharma

IL0011407140

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights results from a long-term follow-up study with JELMYTO® (mitomycin) for pyelocalyceal solution, which is FDA approved for the treatment of low-grade, upper tract urothelial ca...

Read More

UroGen Pharma

Technical Analysis Termsheet Terminal

Permalink

Thu, 30.01.2025 UroGen Pharma

IL0011407140

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate at the following investor conferences in February: Guggenheim Securities SMID Cap Biotech Conference Date / Time: February 5, 2025...

Read More

UroGen Pharma

Technical Analysis Termsheet Terminal

Permalink

Wed, 15.01.2025 UroGen Pharma

IL0011407140

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the 3-month complete response (CR) rate and 12-month durability of response from the Phase 3 ENVISION study of investigational drug UGN-102 in patients with low-grad...

Read More

UroGen Pharma

Technical Analysis Termsheet Terminal

Permalink

Fri, 06.12.2024 UroGen Pharma

IL0011407140

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 35 new employees in connection with their employment with UroGen. These new team members will support the ongo...

Read More

UroGen Pharma

Technical Analysis Termsheet Terminal

Permalink

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

SMART * AD

EN GIF 970X250

P R O D U C T S U G G E S T I O N S

Report a bug

First Name *

Last Name

Email *

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Page URL

Paste the page URL here

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

Important note

You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .

Understood and confirmed *

I would like to continue *

Continue

Submit improvement suggestion/new feature

Please log in to your user account. This will allow us to contact you in case of any queries.

I would like to remain anonymous.

Subject *

e.g. New calculation method for Risk-of-Ruin-Calculator

View/Tool *

This view/tool

Another page/tool

Link to view/tool

View/Tool (specify URL/link)

Description of the proposed change/feedback *

The more comprehensible the description, the faster a feasibility check can be carried out.

General feedback on the view/tool/component/content *

Use this feedback text field for general or supplementary information

Would you use the tool and recommend it if necessary? *

Your opinion is valuable. Feel free to share it with us.

Your opinion is important to us!

FAQ

You are interested

Do you have a request? Get in contact with us

You are already a member?

Who is online? Community stats (Snapshot): 3.045 Visitors - 12.786 Registered members - 14 New registrations (Welcome!)

ayondo® 2025 - Est.: 2008 - Technology provider, social network, trader community and online platform for investors with an affinity for the stock market - Information, data and news network - Multi-award-winning international business model - Proprietary technology - Fintech pioneer and innovation driver for disruptive technologies - Made in Germany | AI First | NextGen-Finovator

Made in Germany

ayondo-prime a²

Useful Links

About Us

Vision/Mission

Imprint

Legal

Terms of service

Data Protection

Cookie Guidelines

Privacy

Contact

MetaTrader 4

MetaTrader 5

ActivTrader

Education

Tools

Product Universe

FAQ

Fast lane

https://ayon.do/v

https://ayon.do/r

ayondo® - my community, my spirit

Social Media Links

Newsletter

ayondo® is a trademark of RSQ Technology Ventures GmbH ("RSQ"). RSQ is the operator of the Internet presence ayondo.com and its sub-sites. ayondo® as a brand represents a community of interest that is connected via a social network and common interests.

Financial literacy represents a key qualification. A key objective is to promote financial knowledge and financial literacy. The content published on the online portal is aimed at people who are interested in information and education in the field of investment, investing and trading and related topics. As a precautionary measure, we would like to point out that none of the content available on ayondo.com can be interpreted as a recommendation or invitation to buy or sell financial instruments, nor does it constitute any other advisory service. An explicit recommendation to use a particular service, information or financial instruments is not made.

Inasmuch as investment brokerage within the meaning of Section 2 (2) No. 3 of the German Securities Trading Act (WpIG) is provided via the online portal ayondo.com, RSQ acts as a contractually bound broker pursuant to Section 3 (2) WpIG. This service is provided exclusively for the account and under the liability of DonauCapital Wertpapier GmbH, Passauer Str. 5, 94161 Ruderting. In this case, the contractual partner of the customer is exclusively DonauCapital Wertpapier GmbH.

RSQ is entered as a contractually bound intermediary of DonauCapital Wertpapier GmbH in the public register maintained by the Federal Financial Supervisory Authority (BaFin) on the Internet. The register can be viewed at www.bafin.de.

If interested parties wish to take advantage of securities services with reference to CFD or FX trading, there is the option to consider offers from our cooperation partners for this purpose. Provided that this option is used, RSQ will broker trading accounts to the ActivTrades group of companies.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74% and 89% of all retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

©ayondo · THE Social Trading Pioneer · FinTech made in Germany · 2025

Consumer information

Imprint

smart.AD

Candlestick Cheatsheet
(02/2023)

Math of Gains and Losses
(02/2023)

FX-Secrets
(02/2023)

Product search
(02/2023)

Risk of Ruin
(03/2023)

Trade Calculator
(03/2023)

Suggest a Product
(03/2023)

Quality Matrix
(03/2023)

ChatGPT ayondo
(02/2023)

GPT-FAQ
(03/2023)

MQL AI
(05/2023)

MQL Library
(06/2023)

Visual Sitemap
(06/2023)

2min's FF
(07/2023)

Vola Hist
(08/2023)

DAX-Statistics
(09/2023)

Technical Analysis
(09/2023)

Technical Analysis-pro
(10/2023)

TransparentShare
(11/2023)

Dashboards^pro
(12/2023)

Most Popular
(12/2023)

Pinned⁺
(12/2023)

Bookmarks⁺
(12/2023)

NYSE A-Z
(12/2023)

PineScript AI
(Q1/2024)

SSR ^{First Timer}
(Q1/2024)

AIT-Dashboard
(Q1/2024)

Trading Simulator
(Q2/2024)

Constituents
(Q2/2024)

X-Billboard
(Q2/2024)